Cipla, one of India’s leading pharmaceutical companies, reported a 49% rise in its consolidated net profit for Q3 FY25, reaching Rs 1,571 crore. This is a significant jump compared to Rs 1,056 crore in the same quarter last year and also surpasses market estimates of Rs 1,225 crore as polled by Moneycontrol.
It reported the highest-ever quarterly revenue of Rs 7,073 crore, a rise of 7% over Rs 6,604 crore recorded in Q3 FY24; this is above analysts’ estimate of Rs 6,925 crore.
On the consolidated basis, Cipla’s EBITDA for the quarter rose close to 16% YoY at Rs 1,989 crore. EBITDA margin came in higher at 28.1 percent from 26.3 percent during the corresponding period last year. The total expenses stood higher by 5 percent at Rs 5,378 crore as it sees higher operational costs.
The EPS of the company for this quarter was Rs 19.45, reflecting strong profitability. Strong show by Cipla lifted investor confidence. Cipla’s shares, after touching an intraday low of Rs 1,367 rebounded as strongly to trade at Rs 1,470, up by over 5 percent at 2:16 pm on January 28.
Do you have a news tip for Lakshmishree reporters? Please email us at media@lakshmishree.com
Source: Moneycontrol
News Desk
